CanSino Biologics announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate (Menhycia(R))  Vaccine has recently received the drug registration certificate granted by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) of Argentina.

This approval represents another important milestone in the international development of CanSinoBIO's innovative vaccine products and further strengthens the Company's presence in South America. It also reflects the effectiveness of the company's internationalisation strategy as it advances deeply into diversified cooperation models, including technology transfer, intermediate product supply, and finished product supply.

Notably, Argentina was selected based on its favourable market fundamentals and strategic importance. According to market research firm Grand View Research, Argentina's meningococcal vaccine market was valued at approximately $43.8 million in 2025 and is projected to reach $74.6 million by 2033, representing a compound annual growth rate (CAGR) of 6.3 per cent. The introduction of Menhycia(R) aligns with growing regional demand for high-quality vaccines and is expected to improve access to meningococcal immunisation in the country.

Menhycia(R), the first quadrivalent meningococcal conjugate vaccine approved in China, has demonstrated significant clinical advantages in preventing meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W135. The vaccine provides stronger immune responses, longer-lasting protection, and the ability to reduce bacterial carriage. Currently, it is approved for use in children aged 3 months to 6 years (83 months) in China.

Concurrently, CanSinoBIO has completed clinical studies for age expansion of Menhycia(R) to cover individuals aged 7 to 59 years and has obtained the clinical summary report. The company is actively pursuing supplementary applications, which are expected to further broaden the product's target population coverage.